Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28728827 | 0.90 | PDE4D (0.52) | PDE4DKDM4EPOLBL3MBTL1KMT2A | |
| SCHEMBL31332897 | 0.81 | L3MBTL1 (0.46) | PDE4DKDM4EPOLBL3MBTL1KMT2A | |
| SCHEMBL1412585 | 0.81 | PDE4D (0.44) | PDE4DKDM4EPOLBL3MBTL1KMT2A | |
| SCHEMBL1412516 | 0.79 | SMN1; SMN2 (0.51) | KDM4EPOLBL3MBTL1MAPTCYP1A2 | |
| SCHEMBL1412427 | 0.77 | KDM4E (0.44) | PDE4DKDM4EPOLBKMT2AMEN1 | |
| SCHEMBL31728508 | 0.75 | KDM4E (0.40) | PDE4DKDM4EPOLBL3MBTL1KMT2A | |
| SCHEMBL1412595 | 0.75 | KDM4E (0.43) | PDE4DKDM4EPOLBL3MBTL1KMT2A | |
| SCHEMBL21572852 | 0.74 | ALDH1A1 (0.56) | PDE4DKDM4EKMT2AMEN1MAPT | |
| SCHEMBL3033682 | 0.72 | — | — | |
| SCHEMBL14711407 | 0.71 | TARBP2 (0.54) | KDM4EPOLBL3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115490644-B | 1,2, 3-Triazole-4-hydrazide Schiff base fluorescent probe and preparation method and application thereof | 海南师范大学 | 2024-09-24 | — | — | CN | claimed |
| CN-115490644-A | 1,2, 3-triazole-4-hydrazide Schiff base fluorescent probe as well as preparation method and application thereof | 海南师范大学 | 2022-12-20 | — | — | CN | claimed |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-03 | — | — | US | disclosed |
| CN-115490644-B | 1,2, 3-Triazole-4-hydrazide Schiff base fluorescent probe and preparation method and application thereof | 海南师范大学 | 2024-09-24 | — | — | CN | disclosed |
| CN-112638376-B | Substituted tetrahydrocyclopenta [ c ] pyrroles, substituted dihydropyrrolidines, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118307534-A | LTA4H inhibitors and uses thereof | 上海海雁医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| EP-3929194-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-110139862-B | Substituted bicyclic heterocyclic derivatives useful as ROMK channel inhibitors | 百时美施贵宝公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20230365531-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMO VIRUS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20090042726-A1 | Novel Herbicides | SYNGENTA LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042726-A1 | Novel Herbicides | SYNGENTA LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| EP-1991542-A1 | HERBICIDAL ISOXAZOLINE COMPOUNDS | Syngenta Limited (GB) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| EP-1965644-A1 | NOVEL HERBICIDES | Syngenta Limited (GB) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007096576-A1 | HERBICIDAL ISOXAZOLINE COMPOUNDS | SYNGENTA LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096576-A1 | HERBICIDAL ISOXAZOLINE COMPOUNDS | SYNGENTA LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007071900-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071900-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365531-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMO VIRUS | METAP1, SARS1, RTF1 | PDE4D 3582/4885KDM4E 3953/4885POLB 381/4885 |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | PDE4D 1364/4885KDM4E 3111/4885POLB 1970/4885 |
| US-20090042726-A1 | Novel Herbicides | DDT, CBR3, CBR1 | PDE4D 1173/4885KDM4E 1271/4885POLB 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.